On January 5, 2018, Melinta Therapeutics, Inc. (NasdaqGS:MLNT) closed the transaction. The company issued 3,127,846 common shares at a price of $13.491712 per share for gross proceeds of $42,200,000 and loan for gross proceeds of $147,800,000 in the transaction. The company has raised a total of $190,000,000 in total financing in the transaction. The company also issued warrants in the transaction. The warrants entitle the holder to purchase 3,792,868 shares of the company at a fixed exercise price of $16.5. The loan with a term of six years bears an interest rate of 11.75% on the initial issue and 14.75% thereafter.